Rationale: Mitochondrial reactive oxygen species (ROS) are implicated in aging, chronic degenerative neurological syndromes, and myopathies. On the basis of free radical hypothesis, dietary, pharmacological, and genetic ROS suppression has been tested to minimize tissue damage, with remarkable therapeutic efficacy. The effects of mitochondrial-specific ROS suppression in primary mitophagic dysfunction are unknown.
M itochondria produce ATP that fuels excitation-contraction coupling. They are also sources of damaging reactive oxygen species (ROS). Preserving cardiac mitochondrial health is, therefore, essential to maintaining normal cardiac function. We recently identified a central role for the mitochondrial fusion protein mitofusin 2 (Mfn2) in mitochondrial quality control signaling. 1 Ablation of Mfn2 in mouse hearts interrupts parkin-mediated mitophagy of damaged organelles, impairing cardiomyocyte respiration and inducing cardiomyopathy.
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Mfn2 dimers form molecular bridges linking cardiomyocyte mitochondria to sarcoplasmic reticulum, 2 which is independent of mitophagy. Calcium microdomains thus created are essential to regulatory bioenergic feedback. When mitochondrial uptake of sarcoplasmic reticulum-derived calcium and the calciumsensitive generation of reduced NADPH are delayed by Mfn2 ablation, mitochondrial production of superoxide (O 2 − ) is transiently increased. However, whether increased ROS contribute to the mitophagic cardiomyopathy provoked by Mfn2 deficiency is unknown. Accordingly, we suppressed mitochondrial ROS in Mfn2 null hearts using transgenically expressed mitochondrial-targeted catalase (mCAT). 3 Remarkably, we observed an inverse dose-response relationship: low mCAT expression
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improved all aspects of cardiac and mitochondrial function, whereas high mCAT expression evoked persistent organ and organelle dysfunction, despite supersuppression of ROS. These results validate the notion that local mitochondrial ROS contribute to mitochondrial degeneration and also uncover an essential role for ROS in mitochondrial quality control signaling.
Methods
Mfn2 loxp/loxp mice crossed onto myh6-driven nuclear-directed Cre (cardiac Mfn2 knockout), ppif null (cyclophilin D knockout), and lowCAT and hiCAT transgenic mice have been described previously. 1, 3, 4 Details of experimental and analytic protocols are in the Online Data Supplement.
Results

Mitochondrial ROS Production Is Increased in Mitophagically Impaired Mfn2-Deficient Hearts
Because superoxide production is transiently increased in hemodynamically stressed young Mfn2-deficient cardiomyocytes, 2 we asked whether ROS are chronically increased because these mice develop their characteristic delayed cardiomyopathy. 1 Basal hydrogen peroxide (H 2 O 2 ) production by Mfn2-deficient cardiac mitochondria (Amplex Red) 5 was increased ≈3-fold over control values (Online Figure I ).
Immunoreactive catalase also increased with Mfn2 deficiency ( Figure 4A and 4B), consistent with an adaptive antioxidant response to chronically increased mitochondrial ROS. 6
Mitochondrial Permeability Transition Pore Inhibition Does Not Prevent Cardiomyopathy in Cardiac Mfn2 Null Mice
Both ROS and altered mitochondrial-sarcoplasmic reticulum interactions can open mitochondrial permeability transition pores (MPTP). [7] [8] [9] In contrast to a previous report, 10 here (Online Figure  IIA) and previously, 2 3, 11, 12 Accordingly, we expressed mCAT in hearts at 2 different expression levels, both of which have improved other murine cardiac disease models. 3 In normal hearts, the mCAT chicken β-actin-driven transgene expressed at ≈10-fold higher levels than the mCAT floxed-stop bacterial artificial chromosome (here in combination with myh6-driven nuclear-targeted Cre), 13 IIIB, IIID, and IIIE), or any measured metric of cardiac or mitochondrial function (vide infra). We expressed lowCAT on the cardiac Mfn2 null background to determine how mitochondrial ROS contributes to the cardiomyopathy caused by cardiac Mfn2 deficiency. As with other cardiac disease models, 3 lowCAT attenuated cardiac enlargement ( Figure 1A ) and cardiac/cardiomyocyte hypertrophy ( Figure 1B ; Online Figure IV ) and improved left ventricular dysfunction ( Figure 1C ). These benefits were associated with normalization of mitochondrial ROS production ( Figure 1D ).
Ignoring Voltaire's aphorism that "better is the enemy of good," we tested ROS supersuppression in Mfn2 deficiency by coexpressing hiCAT. Unexpectedly, reduction of mitochondrial ROS production in Mfn2 null hearts to well below normal levels ( Figure 1H ) failed to improve any aspect of the hallmark cardiomyopathy. Rather, cardiac enlargement in 30-week-old mice was increased further ( Figure 1E and 1F), and the time-dependent decline in ventricular pump function was accelerated ( Figure 1G ). These results reveal an inverse dose-response relationship for catalase-mediated ROS suppression in this mitophagic cardiomyopathy.
Oxidative Protein Damage Is Minimal in Mfn2 Null Hearts
The observation that hiCAT is more effective than lowCAT in suppressing mitochondrial ROS production in Mfn2 null hearts, but is ineffective in rescuing the cardiomyopathy, suggested that ROS cytotoxicity is not causing cardiac failure. Indeed, Mfn2 null cardiac homogenates show no evidence of increased protein S-nitrosylation or oxidation, whereas both are evident in Mfn1/Mfn2 double knockout hearts used as a positive control (Figure 2A ). We confirmed that the hallmark defect in parkin-mediated mitophagy was not affected by lowCAT or hiCAT ( Figure 2B ; positive control is cardiac parkin transgenic mouse heart).
Mitochondrial ROS Production Contributes to Mitochondrial Quality Control
Next, we tested whether mitochondrial-derived ROS were having localized effects on mitochondrial fitness in Mfn2 null hearts. ROS normalization with lowCAT ( Figure 1D ) improved mitochondrial dysmorphology ( Figure 3A ; Online Figure V ), normalized mitochondrial polarization status (a marker of mitochondrial health 14, 15 ; Figure 3B ), and corrected respiratory dysfunction ( Figure 3C ). In contrast, hiCAT expression in Mfn2 null hearts actually exaggerated the characteristic abnormalities in mitochondrial size ( Figure 3D ), depolarization ( Figure 3E ), and respiration ( Figure 3F ). Ultrastructural examination of Mfn2 knockout+hiCAT hearts also revealed giant mitochondria in various states of degeneration (Online Figure V) . Thus, lowCAT improved overall mitochondrial quality control in Mfn2-deficient hearts, whereas hiCAT further impeded it.
We posited that the general benefits of lowCAT on mitochondrial fitness, which can be explained, in part, by modulating mitochondrial damage, might also accrue from relieving the load on compensatory clearance mechanisms invoked by mitophagic dysfunction. Higher levels of autophagosome-associated p62/sequestosome and increased processing of the microtubule-associated protein 1 light chain 3 (LC3) ( Figure 4A and 4B) in Mfn2-deficient hearts indicated that cell-wide autophagy, a potential secondary mechanism for culling damaged mitochondria, 16 is increased. Whereas neither lowCAT nor hiCAT alone affected autophagy, lowCAT expression further increased the ratio of LC3-II/LC3-I when compared with Mfn2 null alone ( Figure 4A ). By contrast, supersuppression of mitochondrial ROS with hiCAT did not improve LC3 processing in Mfn2 knockout hearts ( Figure 4B) , revealing a role for mitochondrial ROS in provoking secondary mitochondrial autophagy. In this context, combined suppression of both primary mitophagy and secondary autophagy is a likely reason why the Mfn2 null cardiomyopathy is aggravated by hiCAT ( Figure 4C ).
Discussion
Hydrogen peroxide can function as a signaling molecule during metabolic stress. 17 Here, we show that the mitophagic cardiomyopathy evoked by cardiomyocyte-specific Mfn2 deletion can benefit from suppression, but not virtual elimination, of mitochondrial H 2 O 2 . There are 3 major findings: (1) ROS-mediated cytotoxicity is not the primary driver of mitophagic cardiomyopathy, which is likely caused by many different forms of mitochondrial dysfunction (including loss of polarization and respiratory impairment that we dissociated from ROS levels using hiCAT) evoked by interrupted culling; (2) high levels of ROS found in Mfn2 null cardiac mitochondria contribute to ongoing mitochondrial damage when clearance is suppressed (because lowCAT normalized these and enhanced mitochondrial fitness); and (3) Some threshold level of mitochondrial ROS is required, likely in combination with other signals, to initiate autophagy as a secondary mechanism for mitochondrial clearance when mitophagy fails. Our discovery of a therapeutic window for mitochondrial ROS suppression validates the idea that low levels of mitochondrial-derived ROS can be therapeutic by promoting mitophagy/autophagy signaling, whereas high levels are deleterious because they produce mitochondrial and cellular toxicity. 18 To our knowledge, this is the first evaluation of the dosedependent effectiveness of ROS suppression in a condition caused by a primary defect in mitochondrial quality control. The bimodal dose-response reveals multiple levels of interconnectedness between mitochondrial dysfunction and culling. To maintain proper cellular homeostasis, mitophagy must selectively target only dysfunctional organelles; polarization status is a central determinant of whether a given mitochondrion will be retained or sequestered and mitophagically eliminated. 14, 15 Mitochondrial inner membrane potential is normally reciprocally related to mitochondrial ROS production; depolarized mitochondria produce toxic ROS that may mark the organelle for parkin-mediated mitophagy. When lack of Mfn2 interrupts normal parkin signaling, chronically increased mitochondrial ROS contributes to mitochondrial damage, establishing a positive feedback loop. Accumulation of depolarized, ROS-producing organelles invokes a backup mechanism for disposing of damaged cellular components, cell-wide autophagy. Suppressing mitochondrial ROS production to levels that are near-normal (as with lowCAT expression) interrupts this vicious cycle ( Figure 4C) .
In contrast, hiCAT expression in Mfn2 knockout hearts dissociates mitochondrial polarization status and ROS production; ROS levels drop to a fraction of normal, despite marked organelle depolarization. Thus, any ROS contribution to the signal for mitochondrial elimination via secondary autophagy is lost, and damaged mitochondria continue to accumulate. These findings provide in vivo evidence for an essential role of mitochondrial-derived ROS in mitochondrial quality control via mitophagy and autophagy. The deleterious effects conferred by mitochondrial ROS supersuppression warrant consideration of antioxidant dose-effect in the heart and other organs when evaluating therapeutics for disorders, such as Parkinson disease or aging, wherein mitophagy defects are central to observed pathology. 
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What Is Known?
• Damaged or senescent mitochondria produce toxic reactive oxygen species (ROS) and have to be culled through mitophagy. • When mitophagy is impaired as in aging or some chronic diseases, ROS levels increase. • Suppressing mitochondrial ROS has been beneficial in experimental aging and disease models.
What New Information Does This Article Contribute?
• Mitochondrial ROS toxicity is not a major direct cause of the cardiomyopathy that follows suppression of mitophagy. • Mitochondrial ROS contribute to mitochondrial dysfunction in mitophagically impaired hearts, which is relieved by ROS normalization with mitochondrial catalase. • ROS supersuppression with highly expressed catalase interrupts compensatory mitochondrial autophagy, thereby aggravating mitophagic cardiomyopathy.
The free radical hypothesis implicating ROS in aging and numerous chronic diseases is widely accepted and has spawned attempts to prevent senescence or organ degeneration by ROS scavenging. However, ROS may also act as indicators of cell/ organelle damage, thereby providing a signal for necessary repair or removal. Under this circumstance, overly aggressive ROS suppression might conceivably interfere with normal adaptive responses. In our study we have, for the first time, validated this scenario. First, we show that mitochondrial ROS production is chronically increased in the mitophagically impaired mitofusin 2-deficient heart model. We then demonstrate that expression of mitochondrial-directed catalase at levels that normalize ROS corrects all mitochondrial abnormalities and prevents the cardiomyopathy evoked by mitofusin 2 deletion. Strikingly however, expression of mitochondrial-directed catalase at higher levels that supersuppress mitochondrial ROS actually exacerbates mitochondrial and cardiac dysfunction. Mechanistically, this is explained by failure to invoke compensatory autophagy when ROS levels are too low. These findings uncover the essential role for mitochondrial-derived ROS in mitochondrial quality control signaling and provide an example of how excessive suppression of mitochondrial ROS can actually cause harm, sounding a cautionary note for any chronic disease being considered for antioxidant therapy.
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